Kemp Dolliver
Stock Analyst at Brookline Capital
(0.55)
# 3,874
Out of 4,761 analysts
17
Total ratings
33.33%
Success rate
-15.93%
Average return
Main Sectors:
Stocks Rated by Kemp Dolliver
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| YMAB Y-mAbs Therapeutics | Initiates: Buy | $17 | $5.72 | +197.20% | 1 | Dec 5, 2024 | |
| EYEN Eyenovia | Downgrades: Hold | n/a | $1.68 | - | 2 | Nov 15, 2024 | |
| VRCA Verrica Pharmaceuticals | Downgrades: Hold | n/a | $0.74 | - | 2 | Oct 2, 2024 | |
| IBIO iBio, Inc. | Initiates: Buy | $3.6 | $3.48 | +3.45% | 1 | Jul 22, 2024 | |
| DARE Daré Bioscience | Upgrades: Buy | $36 | $3.17 | +1,035.65% | 2 | May 15, 2024 | |
| OTLK Outlook Therapeutics | Upgrades: Buy | $31 | $1.56 | +1,912.82% | 1 | Jan 25, 2024 | |
| CYCC Cyclacel Pharmaceuticals | Downgrades: Hold | n/a | $0.34 | - | 1 | Dec 19, 2023 | |
| LNTH Lantheus Holdings | Initiates: Buy | $100 | $78.23 | +27.83% | 1 | Nov 30, 2023 | |
| EDSA Edesa Biotech | Maintains: Buy | $57 | $2.43 | +2,245.68% | 2 | Oct 12, 2023 | |
| GNLX Genelux | Initiates: Hold | $25 | $4.81 | +419.75% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $17.67 | +6.11% | 1 | Jan 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $8 | $1.07 | +647.66% | 1 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5.65 | $1.41 | +300.71% | 1 | Feb 2, 2022 |
Y-mAbs Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $17
Current: $5.72
Upside: +197.20%
Eyenovia
Nov 15, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.68
Upside: -
Verrica Pharmaceuticals
Oct 2, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.74
Upside: -
iBio, Inc.
Jul 22, 2024
Initiates: Buy
Price Target: $3.6
Current: $3.48
Upside: +3.45%
Daré Bioscience
May 15, 2024
Upgrades: Buy
Price Target: $36
Current: $3.17
Upside: +1,035.65%
Outlook Therapeutics
Jan 25, 2024
Upgrades: Buy
Price Target: $31
Current: $1.56
Upside: +1,912.82%
Cyclacel Pharmaceuticals
Dec 19, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.34
Upside: -
Lantheus Holdings
Nov 30, 2023
Initiates: Buy
Price Target: $100
Current: $78.23
Upside: +27.83%
Edesa Biotech
Oct 12, 2023
Maintains: Buy
Price Target: $57
Current: $2.43
Upside: +2,245.68%
Genelux
May 18, 2023
Initiates: Hold
Price Target: $25
Current: $4.81
Upside: +419.75%
Jan 13, 2023
Initiates: Buy
Price Target: $19
Current: $17.67
Upside: +6.11%
Oct 21, 2022
Assumes: Buy
Price Target: $8
Current: $1.07
Upside: +647.66%
Feb 2, 2022
Initiates: Buy
Price Target: $5.65
Current: $1.41
Upside: +300.71%